Scholar Rock Holding Corp (SRRK) earnings date

Nasdaq · Mid cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 42 days, typically, give or take 10 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Tue, Nov 10, 2026before open 41 8-K
Q2 FY2026Thu, Aug 6, 2026before open 37 8-K
Q1 FY2026Thu, May 7, 2026before open 37 8-K
Q4 FY2025Tue, Mar 3, 2026before open 62 8-K
Q3 FY2025Fri, Nov 14, 2025before open 45 8-K
Q2 FY2025Wed, Aug 6, 2025before open 37 8-K
Q1 FY2025Wed, May 14, 2025before open 44 8-K
Q4 FY2024Thu, Feb 27, 2025before open 58 8-K

What they guided beta

Q3 FY2026 "In alignment with guidance from the European Medicines Agency (EMA), Scholar Rock resubmitted the apitegromab Marketing Authorisation Application (MAA) for the treatment of children and adults living with SMA in October 2026." exhibit
Q3 FY2026 "Following validation of the submission, review of the MAA is underway, and the Company expects a CHMP opinion in the first half of 2027." exhibit
Q3 FY2026 "Scholar Rock expects to have topline data by year end 2026 and plans to share data from this study in early 2027." exhibit
Q3 FY2026 "demand, launch dynamics, patient enrollment trends, market acceptance, coverage and reimbursement, and the timing of an ISEMBYLD-specific J-code; expectations regarding its growth, strategy, progress and timing of its clinical trials and development programs for apitegromab, including its subcutaneous formulation, the potential characteristics and benefits of such formulation, and its engagement with regulators regarding the development path for such formulation, as well as the ongoing Phase 2 OPAL and FORGE trials, and for SRK-439, including the expected timing of topline data from its Phase " exhibit
Q2 FY2026 "These risks and uncertainties include, without limitation, whether preclinical and clinical data, including the results from the Phase 3 SAPPHIRE trial and any results from ongoing or future clinical trials, including the Phase 2 OPAL clinical trial, the Phase 2 FORGE trial and the Phase 1 clinical trial of SRK-439, will be sufficient to support regulatory approval or further development; that preclinical and clinical data, including the results from the Phase 2 or Phase 3 clinical trial of apitegromab, data from any ongoing or future trials of apitegromab or data for SRK-439, are not predicti" exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/SRRK
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/SRRK

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

SRRK earnings date badge

HTML

<a href="https://veritasdata.dev/company/SRRK/"><img src="https://veritasdata.dev/embed/SRRK.svg" alt="SRRK earnings date" width="240" height="56"></a>

Markdown

[![SRRK earnings date](https://veritasdata.dev/embed/SRRK.svg)](https://veritasdata.dev/company/SRRK/)

Script

<script async src="https://veritasdata.dev/embed/SRRK.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/SRRK"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.